Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of autologous cytokine-induced killer cells for acute leukemia
ChiCTR-OON-16009143Phase 3Recruiting
- Sponsor
- Lu Daopei Hospital
- Start
- Sep 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of autologous cytokine-induced killer cells in Acute Leukaemia (2 arms), sponsored by Lu Daopei Hospital. Primary endpoints: Effective rate of minimal residual disease and Two-year continued complete remission rate. Started Sep 2016; status: recruiting.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on ChiCTR-OON-16009143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OON-16009143.